Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Kazdal

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
British Journal of Cancer|January 13, 2026
Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samplesMarkus Ball, Susanne Beck, Darius Wlochowitz, et al.
British Journal of Cancer|March 2, 2026
Correction: Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samplesMarkus Ball, Susanne Beck, Darius Wlochowitz, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2021
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical fieldAnna-Lena Volckmar, Petros Christopoulos, Martina Kirchner, et al.
Nature Communications|April 11, 2026
Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapyJana Samarin, Hana Nůsková, Piotr Fabrowski, et al.
Acta Neuropathologica|September 18, 2021
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma typesPhilipp Sievers, Damian Stichel, Martin Sill, et al.
Translational Lung Cancer Research|May 20, 2021
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinomaDaniel Kazdal, Eugen Rempel, Cristiano Oliveira, et al.
The Journal of Pathology. Clinical Research|March 7, 2025
Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testingUmberto Malapelle, Chien-Chin Chen, Enrique de Álava, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2020
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology StudyAlbrecht Stenzinger, Volker Endris, Jan Budczies, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical ArtifactsDaniel Kazdal, Volker Endris, Michael Allgäuer, et al.
JCO Precision Oncology|March 21, 2024
High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian CancerNicole Pfarr, Karin von Schwarzenberg, Dario Zocholl, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
British Journal of Cancer|January 13, 2026
Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samplesMarkus Ball, Susanne Beck, Darius Wlochowitz, et al.
British Journal of Cancer|March 2, 2026
Correction: Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samplesMarkus Ball, Susanne Beck, Darius Wlochowitz, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2021
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical fieldAnna-Lena Volckmar, Petros Christopoulos, Martina Kirchner, et al.
Nature Communications|April 11, 2026
Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapyJana Samarin, Hana Nůsková, Piotr Fabrowski, et al.
Acta Neuropathologica|September 18, 2021
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma typesPhilipp Sievers, Damian Stichel, Martin Sill, et al.
Translational Lung Cancer Research|May 20, 2021
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinomaDaniel Kazdal, Eugen Rempel, Cristiano Oliveira, et al.
The Journal of Pathology. Clinical Research|March 7, 2025
Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testingUmberto Malapelle, Chien-Chin Chen, Enrique de Álava, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2020
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology StudyAlbrecht Stenzinger, Volker Endris, Jan Budczies, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical ArtifactsDaniel Kazdal, Volker Endris, Michael Allgäuer, et al.
JCO Precision Oncology|March 21, 2024
High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian CancerNicole Pfarr, Karin von Schwarzenberg, Dario Zocholl, et al.
Pageof 12